Skip to content
    AUTL
    Earnings call· Jun 2026(Q2 FY26)

    Autolus Therapeutics Q2 FY26 earnings call AUTL

    Aug 11, 2026 Source

    Executive summary

    Autolus Therapeutics Q2 FY26 — Strong AUCATZYL Sales Growth and Raised Full-Year Guidance

    Autolus Therapeutics delivered a strong second quarter, driven by robust AUCATZYL sales growth and significant gross margin improvement, leading to an upward revision of full-year revenue guidance. The company is expanding its commercial footprint in the U.S. and U.K. while advancing a diverse pipeline of oncology and autoimmune programs, supported by a new strategic financing facility. Management anticipates continued momentum and key clinical data readouts in the coming periods.

    Highlights

    5

    • AUCATZYL net product revenue reached $45.7 million in Q2 FY26, a substantial increase over $26 million in Q1 FY26.

    • First half FY26 AUCATZYL revenue of $71.9 million is close to the full-year revenue of the prior year's launch.

    • Full-year FY26 AUCATZYL revenue guidance raised to $140 million-$150 million, up from $120 million-$135 million.

    • Gross margin improved significantly to 55% in Q2 FY26, up from 6% in Q1 FY26 and negative in prior quarters.

    • Activated over 80 treatment centers by mid-year, exceeding the initial full-year target.

    Concerns

    2

    • Selling, general and administrative expenses increased to $41.2 million in Q2 FY26, up from $30.3 million in Q2 FY25, partly due to one-time restructuring costs.

    • Net loss for Q2 FY26 was $39.1 million, though an improvement from $47.9 million in Q2 FY25.

    Guidance & targets

    12
    CategoryTargetConfidence
    Full-year AUCATZYL Net Product Revenue
    $140M-$150M
    high materiality
    High
    Gross Margin for ALL Business
    65%-70%
    high materiality
    Medium
    Activated Treatment Centers (U.S.)
    90+ centers
    medium materiality
    High
    Activated Treatment Centers (U.K.)
    around 20 centers
    medium materiality
    High
    CATULUS Study (pediatric ALL) Data Readout
    First data readout
    high materiality
    High
    CATULUS Study (pediatric ALL) Filing
    Filing
    high materiality
    High
    LUMINA Study (lupus nephritis) Data Readout
    Data readout
    high materiality
    High
    BOBCAT Study (progressive MS) First Data Update
    12 patients data
    high materiality
    High
    BOBCAT Study (progressive MS) Second Data Update
    18 patients data with longer follow-up
    high materiality
    High
    Pediatric ALL Launch
    Launch
    high materiality
    Medium
    Lupus Indications Launch
    Launch
    high materiality
    Medium
    CATULUS Study (pediatric ALL) Enrollment
    End of enrollment
    medium materiality
    High

    Segment performance

    1
    SegmentRevenueYoYQoQMargin
    AUCATZYL (obe-cel) Product Sales
    Strong sales growth in Q2 FY26, driven by increased adoption in the U.S. and initial positive momentum in the U.K. Gross margin significantly improved due to higher volumes and operational efficiencies. The company exceeded its mid-year target for activated centers in the U.S. and is expanding its U.K. footprint.
    Activated Centers (U.S.): >80Activated Centers (U.K.): approaching 20
    		$45.7M118.7%75.8%55%

    Operational metrics

    10
    Gross Margin
    55%up from 6% in Q1 FY26
    Q2 FY26

    Significant improvement in gross margin for AUCATZYL sales, moving from negative in prior quarters to a healthy positive.

    Cost of Sales
    $20.5Mdown from $24.4M in Q2 FY25
    Q2 FY26

    Decrease in cost of sales primarily due to operational improvements and reduced inventory-related expenses.

    R&D Expense
    $27.9Mvs $27.4M in Q2 FY25
    Q2 FY26

    R&D expense remained relatively flat year-over-year, with some variability related to clinical production and study enrollment.

    SG&A Expense
    $41.2Mup from $30.3M in Q2 FY25
    Q2 FY26

    Increase in SG&A primarily due to commercialization efforts in the U.S. and U.K., and one-time restructuring costs.

    Loss from Operations
    $43.8Mvs $61.2M in Q2 FY25
    Q2 FY26

    Operating loss decreased year-over-year, reflecting improved revenue and gross margin.

    Net Loss
    $39.1Mvs $47.9M in Q2 FY25
    Q2 FY26

    Net loss improved compared to the prior year period.

    Cash, Cash Equivalents and Marketable Securities
    $201.6M
    June 30, 2026

    Balance of cash and equivalents at the end of the quarter, prior to the initial drawdown of the new credit facility.

    Cash Runway
    into Q2 2028
    Q2 FY26

    Expected cash runway based on current resources and initial tranches of the new financing.

    Manufacturing Automation
    very, very high level of automation
    Future

    Plans to implement a significant automation upgrade to the current manufacturing platform to enhance efficiency.

    U.K. Market Size vs U.S.
    1/6
    Current

    Comparison of the U.K. market potential relative to the U.S. based on population.

    Industry KPIs

    5
    MetricValueDetails
    Launch access metrics>80 centerscenters
    Pipeline read out calendarMultiple readouts expected
    Product franchise net sales$45.7MUSD
    Regulatory approvals filingsFiling expected
    Clinical trial efficacy safety dataEarly clinical experience, safety, PK/PD, biomarker data

    Deals & partnerships

    1
    Perceptive AdvisorsStrategic financing facilityUp to $250M in aggregate principal amount5-year

    A 5-year interest-only senior credit facility to provide additional capital for key inflection points and pipeline programs.

    Risks & headwinds

    2
    Seasonality in AUCATZYL salesQ3 and Q4 FY26

    Implied slight decline in Q3/Q4 revenue compared to Q2 based on guidance range.

    Mitigation: Management considers seasonality in guidance and expects continued strong underlying demand and activity.

    Increased SG&A expensesQ2 FY26

    $41.2M in Q2 FY26 vs $30.3M in Q2 FY25

    Mitigation: Partially due to one-time termination-related expenses from a strategic operational efficiency and cost reduction initiative, which are largely behind the company.

    What to watch in Q3 FY26

    5

    AUCATZYL Net Product Revenue

    Q3 FY26
    Current$45.7M (Q2 FY26)
    TargetMaintain strong sales momentum, consistent with raised FY26 guidance of $140M-$150M

    Why it matters

    Verifying continued commercial execution and market adoption, especially given potential seasonality and the significant Q2 step-up.

    Very good question🎣. So when we look at the -- obviously, the first half of the year, we see obviously a pretty significant step-up in Q2. We believe that is in part driven by the positive data that was reported from the real-world experience at the TANDEM meeting and certainly did drive a very significant increase in registrations onto the program in the second half of the first quarter. And those -- obviously, those patients obviously were driving to quite an extent, I think, the very positive outcome we've seen in Q2. So we think that creates a very good foundation for the rest of the year. There is certainly going to be elements of seasonality that we would expect during the course of the year. And so given that, certainly, we've seen that to some extent last year. It is an element that we're considering. And we believe that the guidance that we're providing is reasonable and certainly has an element of prudence as well.

    Q&A highlights

    7

    The high end of the raised FY26 revenue guidance implies a slight decline in Q3/Q4 compared to Q2. Is this conservatism or expected seasonality/one-timers?

    Management confirmed that the Q2 step-up was partly driven by positive real-world data from the TANDEM meeting, leading to increased registrations. They expect elements of seasonality, similar to last year, and the guidance reflects prudence while maintaining confidence in continued activity and demand.

    “There is certainly going to be elements of seasonality that we would expect during the course of the year. And so given that, certainly, we've seen that to some extent last year. It is an element that we're considering. And we believe that the guidance that we're providing is reasonable and certainly has an element of prudence as well.”

    asked by Salim Syed · answered by Christian Itin

    2 min read5 chapters

    Detailed Narrative

    01

    AUCATZYL Commercial Performance and Market Expansion

    Autolus reported strong commercial momentum for AUCATZYL, with Q2 FY26 net product revenue reaching $45.7 million, a significant increase from $26 million in Q1 FY26. First-half revenue totaled $71.9 million, nearly matching the full-year revenue of the prior launch year. This performance led to an upward revision of the full-year FY26 revenue guidance to $140 million-$150 million. The company has expanded its U.S. footprint to over 80 activated centers by mid-year, exceeding its initial full-year target, and expects to reach 90+ centers by year-end. The U.K. launch also shows strong initial adoption, with approximately 20 centers expected to be active by year-end.

    02

    Gross Margin Improvement and Profitability Path

    Gross margin for AUCATZYL improved substantially to 55% in Q2 FY26, up from 6% in Q1 FY26 and negative in prior quarters. This improvement was driven by increased commercial production volume, operating model efficiencies, and cost reduction initiatives, including consolidating clinical trial manufacturing into the Nucleus facility. Management expects gross margin for the adult ALL business to continue improving towards a target of 65%-70% within 12-18 months, which is a key driver for achieving profitability in this business line.

    03

    Pipeline Advancement in Autoimmune and Oncology

    Autolus is advancing a diverse pipeline beyond adult ALL. Key upcoming data readouts include an update on the CARLYSLE study in systemic lupus at the ACR conference by year-end, initial data from the AUTO8 program in light-chain amyloidosis by year-end, and additional analyses from the FELIX study. The BOBCAT study in progressive multiple sclerosis is expected to provide initial data from 12 patients in Q1 2027 and a second update from 18 patients with longer follow-up in H2 2027. The pivotal CATULUS study in pediatric ALL is expected to complete enrollment by year-end, with first data by end of 2027 and filing by end of 2027/early 2028. The LUMINA study in lupus nephritis is anticipated to deliver Phase II data in 2028.

    04

    Strategic Financing and Cash Runway

    The company secured a strategic financing facility with Perceptive Advisors for up to $250 million. An initial $75 million was drawn at closing in July, with an additional $25 million available at option. Further tranches of $150 million are tied to specific revenue milestones. This financing, combined with existing cash and anticipated net revenues, extends Autolus' cash runway into Q2 2028, providing capital to support key clinical data milestones and expansion into new markets.

    05

    Manufacturing Capacity and Automation

    Autolus is well-positioned from a manufacturing capacity perspective, capable of fully serving the ALL market (adult and pediatric) with its current setup. The Nucleus facility has the ability to mobilize additional clean rooms as needed for future expansion beyond ALL. The manufacturing process is already significantly automated, with plans for another substantial automation upgrade over the next 12-15 months to achieve a very high level of automation and further efficiency gains across the entire production and delivery chain.

    AI-generated summary of the company’s earnings call. Not investment advice.